SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets final approval from USFDA for Varenicline Tablets

13 Jun 2023 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Varenicline Tablets, 0.5 mg and 1 mg (USRLD: Chantix Tablets). The product will be launched shortly. Varenicline tablets is indicated to treat smoking addiction. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. 

Varenicline Tablets, 0.5 mg and 1 mg had annual sales of $501 million in the United States (IQVIA MAT March 2023). The group now has 374 approvals and has so far filed over 442 (as of March 31, 2023) ANDAs since the commencement of the filing process in FY 2003-04

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. 

Zydus Lifesciences Share Price

915.45 13.30 (1.47%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×